Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.
Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.
Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.
Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.
Qualigen Therapeutics reported that it received a notification from Nasdaq regarding its failure to file the Annual Report on Form 10-K for the year ending December 31, 2022, as mandated by Nasdaq Rules. The delay in the filing, due to additional information required for the company’s acquisition of a majority interest in NanoSynex, Ltd, resulted in the company filing a Notification of Late Filing on Form 12b-25. While this notification does not immediately affect the Nasdaq listing, failure to regain compliance may lead to delisting. Qualigen is working to file the Form 10-K by June 20, 2023, which would help avoid submitting a formal compliance plan.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
